41479-98-5

Basic information

• Product Name: 2H-Pyran-2-one, 5,6-dihydro-4-hydroxy-6-phenyl-
• CAS NO: 41479-98-5
• Molecular Formula: C11H10O3
• Molecular Weight: 190.199
• Mol File: 41479-98-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2H-Pyran-2-one, 5,6-dihydro-4-hydroxy-6-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-2-one, 5,6-dihydro-4-hydroxy-6-phenyl-(41479-98-5)
• EPA Substance Registry System: 2H-Pyran-2-one, 5,6-dihydro-4-hydroxy-6-phenyl-(41479-98-5)

Safety Data

• Hazardous Substances Data: 41479-98-5(Hazardous Substances Data)

Upstream product

• 5764-85-2 Ethyl 3-hydroxy-3-phenylpropanoate 
• 100-52-7 benzaldehyde 
• 105-45-3 acetoacetic acid methyl ester 
• 53063-63-1 5-hydroxy-3-oxo-5-phenyl-valeric acid methyl ester 

Downstream Products

• 17298-18-9 4-methoxy-6-phenyl-5,6-dihydro-pyran-2-one 
• 1020850-69-4 trifluoromethanesulfonic acid 6-oxo-2-phenyl-3,6-dihydro-2H-pyran-4-yl ester 
• 1312921-06-4 C₁₅H₁₇NO₅ 
• 99275-23-7 4-p-toluenesulfonyloxy-6-phenyl-5,6-dihydro-2H-pyran-2-one 

Relevant articles and documents

Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase

A series of 3,6-disubstituted dihydropyrones were identified as inhibitors of human lactate dehydrogenase (LDH)-A. Structure activity relationships were explored and a series of 6,6-spiro analogs led to improvements in LDHA potency (IC50 50 = 30 nM).

INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE

The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these comp

5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents

The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the tre